InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: None

Friday, 05/27/2016 1:24:02 PM

Friday, May 27, 2016 1:24:02 PM

Post# of 3833
New SEC filing. Very interesting...

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION May 27, 2016
ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Galectin Therapeutics, Inc.
File No. 001-31791 - CF#33590 _____________________
Galectin Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 15, 2016, as amended.
Based on representations by Galectin Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
Exhibit 10.50 through May 1, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Brent J. Fields Secretary

"It is difficult to get a man to understand something, when his salary depends upon his not understanding it."

Upton Sinclair

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News